Efficacy and safety of sunitinib in treatment of advanced or metastatic pheochromocytomas and paragangliomas: A meta-analysis of sunitinib-treated arms from prospective clinical trials

Clicks: 7
ID: 338068
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #441 of 449 articles by views in the journal of clinical endocrinology & metabolism

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 449 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
CONTEXT: Metastatic pheochromocytomas and paragangliomas (mPPGLs) are rare neuroendocrine tumors with limited treatment options. Among the options for the treatment of mPPGLs are tyrosine kinase inhibitors (TKIs), including cabozantinib and sunitinib. However, TKIs have different molecular targets and side effects. Additionally, the evidence supporting their use for these tumors has been limited and of low-quality. OBJECTIVE: To summarize prospective efficacy and safety outcomes of sunitinib among patients with mPPGLs. METHODS: A literature search was conducted to investigate the effects of sunitinib on progression-free survival (PFS) tumor responses and adverse events (AEs) in prospective studies of sunitinib for mPPGLs treatment. Because only one included study had a comparator, quantitative synthesis was performed at the sunitinib-treatment-arm level. RESULTS: Three prospective clinical trials were included in the meta-analysis. The total sample in these studies was 114 patients given sunitinib. The objective response rate was 21.2% (95% CI, 11.7-35.3%), and all the responses were partial, with no complete responses. The stable disease rate was 51.8% (95% CI, 36.8-66.4%). The progressive disease rate was 27.1% (95% CI, 19.5-36.3%). The 12-month PFS rate was 48.2% (95% CI, 38.1-58.5%). The median PFS duration was 11.9 months (95% CI, 6.9-16.9 months). The rate of treatment discontinuation due to AEs was 13.2% (95% CI, 8.1-20.7%). The rate of grade ≥3 adverse events was 57.8% (95% CI, 36.7-76.4%), with substantial heterogeneity (I2 = 86%; P = .001). CONCLUSIONS: Overall, the available low to very low certainty but prospective evidence suggests that sunitinib provides clinically relevant disease control in a subset of patients, characterized by modest objective response rates.
Reference Key
openalex_W7224926870 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Alejandro Román-Gonzaléz, Carlos Esteban Builes-Montaño, Wellgner Fernandes Oliveira Amador, Marta Araujo Castro, Camilo Jiménez
Are you one of these authors? Claim your profile
Journal the journal of clinical endocrinology & metabolism
Year 2026
DOI
10.1210/clinem/dgag446
URL
https://doi.org/10.1210/clinem/dgag446
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.